Lately, UTC Therapeutics has been honored with the "Top Cancer Immunotherapy Solution In Asia 2025" award by the renowned journal《Life Sciences Review. This award is in recognition of UTC Therapeutics’ stellar reputation and trust among patients and industry peers. Meanwhile, Dr.Yangbing Zhao, Chairman and CSO of UTC Therapeutics, Has been featured as the cover star of the latest issue of the magazine and was interviewed in the same edition.

《Life Sciences Review》specializes in the area of life sciences, and is committed to amplifying the reach and influence of the most impactful companies within the industry. Dr. Yangbing Zhao emphasized during the interview, “We don’t just create immunotherapies. We design treatments to tackle the distinct hurdles of solid tumors, where others have struggled for decades.”

With LACO-Stim at its core, UTC Therapeutics is advancing intelligent immunotherapies built to outsmart the most resilient tumors and to bring transformative care within global reach.